NLM Digital Collections

Search

Start Over Subjects Humans ✖Remove constraint Subjects: Humans Subjects Treatment Outcome ✖Remove constraint Subjects: Treatment Outcome Publication Year 2018 ✖Remove constraint Publication Year: <span class="single" data-blrl-single="2018">2018</span>

1. Are you ready to respond?: reports of high harm complications after surgery and invasive procedures

Author(s):
Magee, Mary C., author
Finley, Edward, author
Liberatore, Kim, author
Publication:
[Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, December 2018
Subject(s):
Clinical Deterioration
Failure to Rescue, Health Care -- statistics & numerical data
Intraoperative Complications -- mortality
Intraoperative Complications -- prevention & control
Postoperative Complications -- mortality
Postoperative Complications -- prevention & control
Surgical Procedures, Operative -- adverse effect
Surgical Procedures, Operative -- mortality
Anatomy
Blood Loss, Surgical
Blood Transfusion
Hospital Rapid Response Team
Medical Errors -- prevention & control
Patient Safety
Resuscitation -- methods
Treatment Outcome
Humans
Pennsylvania
United States

2. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 14, 2018
Subject(s):
Genetic Therapy
Leber Congenital Amaurosis -- genetics
Leber Congenital Amaurosis -- therapy
Retinal Diseases -- genetics
Retinal Diseases -- therapy
Retinal Pigment Epithelium -- abnormalities
Mutation
Randomized Controlled Trials as Topic
Treatment Outcome
Visual Acuity
Humans
United States

3. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
Subject(s):
Immunotherapy, Adoptive
Leukemia, B-Cell -- drug therapy
Lymphoma, B-Cell -- drug therapy
Lymphoma, Non-Hodgkin -- drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Adult
Child
Clinical Trials as Topic
Clofarabine -- therapeutic use
Cost-Benefit Analysis
Immunotherapy, Adoptive -- adverse effects
Immunotherapy, Adoptive -- economics
Receptors, Chimeric Antigen -- therapeutic use
Treatment Outcome
Humans
United States

4. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
Subject(s):
Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States

5. Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
Subject(s):
Cystic Fibrosis -- drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator -- therapeutic use
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator -- adverse effects
Treatment Outcome
Humans
United States

6. Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, July 3, 2018
Subject(s):
Calcitonin Gene-Related Peptide Receptor Antagonists -- therapeutic use
Migraine Disorders -- drug therapy
Migraine Disorders -- prevention & control
Calcitonin Gene-Related Peptide Receptor Antagonists -- adverse effects
Chronic Disease
Clinical Trials as Topic
Treatment Outcome
Humans
United States

7. Elagolix for treating endometriosis: final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Endometriosis -- drug therapy
Gonadotropin-Releasing Hormone -- antagonists & inhibitors
Analgesics -- adverse effects
Analgesics -- therapeutic use
Cost-Benefit Analysis
Pain -- drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

8. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Immunologic Factors -- therapeutic use
Immunomodulation
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Treatment Outcome
Humans
United States

9. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Amyloidosis, Familial -- drug therapy
RNA, Small Interfering -- therapeutic use
Amyloid Neuropathies, Familial -- drug therapy
Amyloidosis, Familial -- complications
Clinical Trials as Topic
Cost-Benefit Analysis
RNA, Small Interfering -- adverse effects
RNA, Small Interfering -- economics
Treatment Outcome
Humans
United States

10. Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Androgen Antagonists -- therapeutic use
Prostatic Neoplasms -- drug therapy
Androgen Antagonists -- adverse effects
Cost-Benefit Analysis
Disease Progression
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States